PCSK9 inhibitor Praluent has settled on general hospitals. After registering insurance benefits in June 2021, the landing process is steadily underway. According to related industries, Sanofi-Aventis Korea's Praluent passed the Pharmaceutical Affairs Committee (DC), including Samsung Medical Center, Asan Medical Center, Sinchon Severance Hospital, Bundang Seoul National University Hospital, Chonnam National University Hospital, and Pusan National University Hospital. The drug was approved in Korea in January 2017, but was listed last year. Amgen Korea's Repatha, which was approved around the same time, was first registered as a Homozygous Family Hypercholesterolemia (HOFH) indication in August 2018.

In